Nektar Therapeutics Increase (Decrease) in Accrued Liabilities
Nektar Therapeutics (NKTR) reported Increase (Decrease) in Accrued Liabilities of -$17.12 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2024-03-05
- Nektar Therapeutics increase (decrease) in accrued liabilities for the quarter ending 2015-03-31 was $1.81M, a 161.33% increase year-over-year.
- Nektar Therapeutics increase (decrease) in accrued liabilities for the quarter ending 2014-12-31 was -$1.39M.
- Nektar Therapeutics increase (decrease) in accrued liabilities for the quarter ending 2014-09-30 was $1.98M.
- Nektar Therapeutics increase (decrease) in accrued liabilities for the quarter ending 2014-06-30 was -$1.01M, a 122.83% decline year-over-year.
- Nektar Therapeutics increase (decrease) in accrued liabilities for fiscal 2023 was -$17.12M.
- Nektar Therapeutics increase (decrease) in accrued liabilities for fiscal 2022 was -$19.95M.
- Nektar Therapeutics increase (decrease) in accrued liabilities for fiscal 2021 was -$22.93M.
- Nektar Therapeutics increase (decrease) in accrued liabilities for fiscal 2014 was $273.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$17.12M 10-K · filed 2024-03-05 | |||
| 2022-12-31 | -$19.95M 10-K · filed 2024-03-05 | |||
| 2021-12-31 | -$22.93M 10-K · filed 2024-03-05 | |||
| 2015-03-31 | $1.81M 10-Q · filed 2015-05-01 | $417.00K derived: sum of 2 quarters · filed 2015-05-01 | $2.40M derived: sum of 3 quarters · filed 2015-05-01 | $1.39M derived: sum of 4 quarters · filed 2015-05-01 |
| 2014-12-31 | -$1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $587.00K derived: sum of 2 quarters · filed 2015-02-26 | -$420.00K derived: sum of 3 quarters · filed 2015-02-26 | $273.00K 10-K · filed 2015-02-26 |
| 2014-09-30 | $1.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $974.00K derived: sum of 2 quarters · filed 2014-11-07 | $1.67M 10-Q · filed 2014-11-07 | -$2.99M derived: sum of 4 quarters · filed 2015-05-01 |
| 2014-06-30 | -$1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | -$314.00K 10-Q · filed 2014-08-01 | -$4.97M derived: sum of 3 quarters · filed 2015-05-01 | -$5.51M derived: sum of 4 quarters · filed 2015-05-01 |
| 2014-03-31 | $693.00K 10-Q · filed 2015-05-01 | -$3.96M derived: sum of 2 quarters · filed 2015-05-01 | -$4.50M derived: sum of 3 quarters · filed 2015-05-01 | -$92.00K derived: sum of 4 quarters · filed 2015-05-01 |
| 2013-12-31 | -$4.66M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | -$5.20M derived: sum of 2 quarters · filed 2015-02-26 | -$785.00K derived: sum of 3 quarters · filed 2015-02-26 | -$1.92M 10-K · filed 2015-02-26 |
| 2013-09-30 | -$539.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $3.87M derived: sum of 2 quarters · filed 2014-11-07 | $2.74M 10-Q · filed 2014-11-07 | $4.70M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | $4.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-01 | $3.28M 10-Q · filed 2014-08-01 | $5.24M derived: sum of 3 quarters · filed 2015-02-26 | $4.58M derived: sum of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | -$1.13M 10-Q · filed 2014-05-08 | $830.00K derived: sum of 2 quarters · filed 2015-02-26 | $174.00K derived: sum of 3 quarters · filed 2015-02-26 | -$729.00K derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $1.30M derived: sum of 2 quarters · filed 2015-02-26 | $401.00K derived: sum of 3 quarters · filed 2015-02-26 | $1.50M 10-K · filed 2015-02-26 |
| 2012-09-30 | -$656.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$1.56M derived: sum of 2 quarters · filed 2013-11-07 | -$465.00K 10-Q · filed 2013-11-07 | -$5.69M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-06-30 | -$903.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $191.00K 10-Q · filed 2013-08-09 | -$5.03M derived: sum of 3 quarters · filed 2014-02-27 | -$1.17M derived: sum of 4 quarters · filed 2014-02-27 |
| 2012-03-31 | $1.09M 10-Q · filed 2013-05-09 | -$4.13M derived: sum of 2 quarters · filed 2014-02-27 | -$264.00K derived: sum of 3 quarters · filed 2014-02-27 | $146.00K derived: sum of 4 quarters · filed 2014-02-27 |
| 2011-12-31 | -$5.22M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | -$1.36M derived: sum of 2 quarters · filed 2014-02-27 | -$948.00K derived: sum of 3 quarters · filed 2014-02-27 | $1.01M 10-K · filed 2014-02-27 |
| 2011-09-30 | $3.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $4.28M derived: sum of 2 quarters · filed 2012-11-09 | $6.24M 10-Q · filed 2012-11-09 | $3.83M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-06-30 | $410.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $2.37M 10-Q · filed 2012-08-09 | -$36.00K derived: sum of 3 quarters · filed 2013-03-01 | $3.04M derived: sum of 4 quarters · filed 2013-03-01 |
| 2011-03-31 | $1.96M 10-Q · filed 2012-05-04 | -$446.00K derived: sum of 2 quarters · filed 2013-03-01 | $2.63M derived: sum of 3 quarters · filed 2013-03-01 | $2.29M derived: sum of 4 quarters · filed 2013-03-01 |
| 2010-12-31 | -$2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01 | $671.00K derived: sum of 2 quarters · filed 2013-03-01 | $329.00K derived: sum of 3 quarters · filed 2013-03-01 | $1.68M 10-K · filed 2013-03-01 |
| 2010-09-30 | $3.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $2.74M derived: sum of 2 quarters · filed 2011-11-04 | $4.09M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | -$342.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | $1.01M 10-Q · filed 2011-08-05 | ||
| 2010-03-31 | $1.35M 10-Q · filed 2011-04-29 | |||
| 2009-12-31 | -$4.19M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |